CTOs on the Move

Adial Pharmaceuticals

www.adialpharma.com

 
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.adialpharma.com
  • 1180 Seminole Trail Ste 495
    Charlottesville, VA USA 22901
  • Phone: 434.422.9800

Executives

Name Title Contact Details

Similar Companies

MK Education

MK Education is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Niadyne

Niadyne is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athenex

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.

Success TMS

Get relief from depression in under 8 weeks. Safe & FDA approved. Covered by Insurance & Medicare. Get your FREE consultation. Book an appointment Today!